Achieve Life Sciences (ACHV) Change in Receivables (2010 - 2020)
Achieve Life Sciences (ACHV) recorded quarterly Change in Receivables of -$8000.0 in Q1 2020, up 55.56% on a QoQ basis from -$18000.0 in Q4 2018.
Achieve Life Sciences (ACHV) Change in Receivables (2010 - 2020) Analysis & Trends
Achieve Life Sciences has disclosed Change in Receivables across 10 years of filings, most recently posting -$8000.0 for Q1 2020.
- Quarterly Change in Receivables changed N/A year-over-year to -$8000.0 in Q1 2020, while the trailing twelve-month figure through Sep 2020 was -$26000.0 (changed N/A YoY) and the FY2019 annual result came in at $1000.0, up 150.0% from the prior year.
- Change in Receivables improved to -$8000.0 in Q1 2020, from -$18000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $401000.0 in Q3 2017 and troughed at -$241000.0 in Q1 2017.
- A 4-year average of $40181.8 and a median of -$5000.0 in 2018 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2016 — Change in Receivables jumped 31900.0% — and 2017, when it slumped 210.05%.
- Tracing ACHV's Change in Receivables over 4 years: stood at $320000.0 in 2016, then slumped by 148.44% to -$155000.0 in 2017, then jumped by 88.39% to -$18000.0 in 2018, then jumped by 55.56% to -$8000.0 in 2020.
- Business Quant data shows ACHV's Change in Receivables at -$8000.0 in Q1 2020, -$18000.0 in Q4 2018, and -$5000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -8,000.00 |
| Mar 31, 2020 | -8,000.00 |
| Dec 31, 2018 | -18,000.00 |
| Dec 31, 2018 | -18,000.00 |
| Sep 30, 2018 | -5,000.00 |
| Sep 30, 2018 | -5,000.00 |
| Dec 31, 2017 | -155,000.00 |
| Dec 31, 2017 | -155,000.00 |
| Sep 30, 2017 | 401,000.00 |
| Sep 30, 2017 | 401,000.00 |
| Jun 30, 2017 | 4,000.00 |
| Jun 30, 2017 | 4,000.00 |
| Mar 31, 2017 | -241,000.00 |
| Mar 31, 2017 | -241,000.00 |
| Dec 31, 2016 | 320,000.00 |
| Dec 31, 2016 | 320,000.00 |
| Sep 30, 2016 | -149,000.00 |
| Sep 30, 2016 | -149,000.00 |
| Jun 30, 2016 | 74,000.00 |
| Jun 30, 2016 | 74,000.00 |